Lost in Translation: The Need for Better Tools

ATLA Alternatives to Laboratory Animals

Volumn 42, Issue 4, 2014, Pages P41-P45

  Penco, Susanna ^a   Venco, Elena ^b   Lio, Alfredo ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b Venco   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL; ANIMAL MODEL; HUMAN; TRANSLATIONAL RESEARCH;

ANIMALS; HUMANS; MODELS, ANIMAL; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84944324790     PISSN: 02611929     EISSN: 26323559     Source Type: Journal    
DOI: 10.1177/026119291404200411     Document Type: Article

References (72)

1. Esserman L.J. & Woodcock J. (2011). Accelerating identification and regulatory approval of investigational cancer drugs. JAMA 306, 2608–2609.
2. Li A.P. (2004). In vitro approaches to evaluate ADMET drug properties. Current Topics in Medicinal Chemistry 4, 701–706.
3. Berlin J.A., Glasser S.C. & Ellenberg S.S. (2008). Adverse event detection in drug development: Recommendations and obligations beyond phase 3. American Journal of Public Health 98, 1366–1371.
4. Hartung T. (2013). Look back in anger — What clinical studies tell us about preclinical work. ALTEX 30, 275–291.
5. Arrowsmith J. (2012). A decade of change. Nature Reviews Drug Discovery 11, 17–18.
6. Engle S.J. & Puppala D. (2013). Integrating human pluripotent stem cells into drug development. Cell Stem Cell 12, 669–677.
7. Paul S.M., Mytelka D.S., Dunwiddie C.T., Persinger C.C., Munos B.H., Lindborg S.R. & Schacht A.L. (2010). How to improve R&D productivity: The pharmaceutical industry's grand challenge. Nature Reviews Drug Discovery 9, 203–214.
8. Breslin S. & O'Driscoll L. (2013). Three-dimensional cell culture: The missing link in drug discovery. Drug Discovery Today 18, 240–249.
9. Arya N., Sardana V., Saxena M., Rangarajan A. & Katti D.S. (2012). Recapitulating tumour microenvironment in chitosan–gelatin three-dimensional scaffolds: An improved in vitro tumour model. Journal of the Royal Society, Interface 9, 3288–3302.
10. Knight A. (2007). Animal experiments scrutinised: Systematic reviews demonstrate poor human clinical and toxicological utility. ALTEX 24, 320–325.
11. van Vliet E. (2011). Current standing and future prospects for the technologies proposed to transform toxicity testing in the 21st century. ALTEX 28, 17–44.
12. Mestas J. & Hughes C.C. (2004). Of mice and not men: Differences between mouse and human immunology. Journal of Immunology 172, 2731–2738.
13. Brady C.A. (2008). Of mice and men: The potential of high-resolution human immune cell assays to aid the pre-clinical to clinical transition of drug development projects. Drug Discovery World, Winter 2008/09. London, UK: RJ Communications & Media Ltd. Available at: http://ddw.net-genie.co.uk/enabling_technologies/261930/of_mice_and_men.html (Accessed 31.08.14).
14. Mouse Genome Sequencing Consortium (2002). Initial sequencing and comparative analysis of the mouse genome. Nature, London 420, 520–562.
15. Nelson D.R., Koymans L., Kamataki T., Stegeman J.J., Feyereisen R., Waxman D.J., Waterman M.R., Gotoh O., Coon M.J., Estabrook R.W., Gunsalus I.C. & Nebert D.W. (1996). P450 superfamily: Update on new sequences, gene mapping, accession numbers and nomenclature. Pharmacogenetics 6, 1–42.
16. Lindberg L.P. & Negishi M. (1989). Alteration of mouse cytochrome P450coh substrate specificity by mutation of a single amino-acid residue. Nature, London 339, 632–634.
17. Schnabel J. (2008). Neuroscience: Standard model. Nature, London 454, 682–685.
18. Gordon, P.H., Moore, D.H., Miller, R.G., Florence, J.M., Verheijde, J.L., Doorish, C., Hilton, J.F., Spitalny, G.M., MacArthur, R.B., Mitsumoto, H., Neville, H.E., Boylan, K., Mozaffar, T., Belsh, J.M., Ravits, J., Bedlack, R.S., Graves, M.C., McCluskey, L.F., Barohn, R.J., Tandan, R.; Western ALS Study Group (2007). Efficacy of minocycline in patients with amyotrophic lateral sclerosis: A phase III randomised trial. Lancet Neurology 6, 1045–1053.
19. Doody, R.S., Raman, R., Farlow, M., Iwatsubo, T., Vellas, B., Joffe, S., Kieburtz, K., He, F., Sun, X., Thomas, R.G., Aisen, P.S.; Alzheimer's Disease Cooperative Study Steering Committee, Siemers, E., Sethuraman, G., Mohs, R.; Semagacestat Study Group (2013). A phase 3 trial of semagacestat for treatment of Alzheimer's disease. New England Journal of Medicine 369, 341–350.
20. Gawrylewsky A. (2007). The trouble with animal models — Why did human trials fail? The Scientist, July 2007. Midland, Ontario, Canada: LabX Media Group. Available at: http://www.the-scientist.com/?articles.view/articleNo/25184/title/The-Trouble-with-Animal-Models/ (Accessed 31.08.14).
21. Perel P., Roberts I., Sena E., Wheble P., Briscoe C., Sandercock P., Macleod M., Mignini L.E., Jayaram P. & Khan K.S. (2007). Comparison of treatment effects between animal experiments and clinical trials: Systematic review. BMJ 334, 197.
22. Pound P., Ebrahim S., Sandercock P., Bracken M.B., Roberts I.; Reviewing Animal Trials Systematically (RATS) Group (2004). Where is the evidence that animal research benefits humans? BMJ 328, 514–517.
23. Greek R. & Hansen L. (2013). Questions regarding the predictive value of one evolved complex adaptive system for a second: Exemplified by the SOD1 mouse. Progress in Biophysics & Molecular Biology 113, 231–253.
24. Seymour M. (2009). The best model for humans is human — How to accelerate early drug development safely. ATLA 37, Suppl. 1, 61–65.
25. Lin J.F. & Lu A.Y.H. (1997). Role of pharmacokinetics and metabolism in drug discovery and development. Pharmacological Reviews 49, 403–449.
26. Sutherland M.L., Fabre K.M. & Tagle D.A. (2013). The National Institutes of Health Microphysiological Systems Program focuses on a critical challenge in the drug discovery pipeline. Stem Cell Research & Therapy 4, Suppl. 1, I1.
27. Seok J., Warren H.S., Cuenca A.G., Mindrinos M.N., Baker H.V., Xu W., Richards D.R., McDonald-Smith G.P., Gao H., Hennessy L., Finnerty C.C., López C.M., Honari S., Moore E.E., Minei J.P., Cuschieri J., Bankey P.E., Johnson J.L., Sperry J., Nathens A.B., Billiar T.R., West M.A., Jeschke M.G., Klein M.B., Gamelli R.L., Gibran N.S., Brownstein B.H., Miller-Graziano C., Calvano S.E., Mason P.H., Cobb J.P., Rahme L.G., Lowry S.F., Maier R.V., Moldawer L.L., Herndon D.N., Davis R.W., Xiao W., Tompkins R.G.; Inflammation and Host Response to Injury, Large Scale Collaborative Research Program (2013). Genomic responses in mouse models poorly mimic human inflammatory diseases. Proceedings of the National Academy of Sciences of the USA 110, 3507–3512.
28. Sena E., Wheble P., Sandercock P. & Macleod M. (2007). Systematic review and meta-analysis of the efficacy of tirilazad in experimental stroke. Stroke 38, 388–394.
29. van der Worp H.B., Howells D.W., Sena E.S., Porritt M.J., Rewell S., O'Collins V. & Macleod M.R. (2010). Can animal models of disease reliably inform human studies? PLoS Medicine 7, e1000245.
30. Bailey J. & Taylor K. (2009). The SCHER report on non-human primate research — Biased and deeply flawed. ATLA 37, 427–435.
31. Greek R. & Menache A. (2013). Systematic reviews of animal models: Methodology versus epistemology. International Journal of Medical Sciences 10, 206–221.
32. Kola I. & Landis J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug Discovery 3, 711–715.
33. Mak I.W., Evaniew N. & Ghert M. (2014). Lost in translation: Animal models and clinical trials in cancer treatment. American Journal of Translational Research 6, 114–118.
34. Enna S.J. & Williams M. (2009). Defining the role of pharmacology in the emerging world of translational research. Advances in Pharmacology 57, 1–30.
35. Lazic S.E. & Essioux L. (2013). Improving basic and translational science by accounting for litter-to-litter variation in animal models. BMC Neuroscience 14, 37.
36. Leist M. & Hartung T. (2013). Inflammatory findings on species extrapolations: Humans are definitely no 70-kg mice. Archives of Toxicology 87, 563–567.
37. Aggarwal B.B., Danda D., Gupta S. & Gehlot P. (2009). Models for prevention and treatment of cancer: Problems vs promises. Biochemical Pharmacology 78, 1083–1094.
38. Coleman R.A. (2011). Human tissue in the evaluation of safety and efficacy of new medicines: A viable alternative to animal models? ISRN Pharmaceutics 2011, 806789.
39. Li A.P. (2014). Biomarkers and human hepatocytes. Biomarkers in Medicine 8, 173–183.
40. Hyman S.E. (2012). Revolution stalled. Science Translational Medicine 4, 155cm11.
41. Stingl L., Völkel M. & Lindl T. (2009). 20 years of hypertension research using genetically modified animals: No clinically promising approaches in sight. ALTEX 26, 41–51.
42. Bhogal N. & Combes R. (2006). The relevance of genetically altered mouse models of human disease. ATLA 34, 429–454.
43. Anon. (2013). Drug testing should be with human iPS cells. Drug Discovery & Development, 06.12.13. Rockaway, NJ, USA: Advantage Media. Available at: http://www.dddmag.com/news/2013/12/drug-testing-should-be-human-ips-cells (Accessed 31.08. 14).
44. Mertens J., Stüber K., Wunderlich P., Ladewig J., Kesavan J.C., Vandenberghe R., Vandenbulcke M., van Damme P., Walter J., Brüstle O. & Koch P. (2013). APP processing in human pluripotent stem cell-derived neurons is resistant to NSAID-based γ-sec-retase modulation. Stem Cell Reports 1, 491–498.
45. Rice J. (2012). Animal models: Not close enough. Nature, London 484, S9.
46. Friese M.A., Montalban X., Willcox N., Bell J.I., Martin R. & Fugger L. (2006). The value of animal models for drug development in multiple sclerosis. Brain 129, 1940–1952.
47. Beal M.F. (2010). Parkinson's disease: A model dilemma. Nature, London 466, S8–S10.
48. Grass G.M. & Sinko P.J. (2002). Physiology-based pharmacokinetic simulation modelling. Advanced Drug Delivery Reviews 43, 433–451.
49. Akabane T., Tabata K., Kadono K., Sakuda S., Terashita S. & Teramura T. (2010). A comparison of pharmacokinetics between humans and monkeys. Drug Metabolism & Disposition 38, 308–316.
50. Cao X., Gibbs S.T., Fang L., Miller H.A., Landowski C.P., Shin H.C., Lennernas H., Zhong Y., Amidon G.L., Yu L.X. & Sun D. (2006). Why is it challenging to predict intestinal drug absorption and oral bioavailability in human using rat model. Pharmaceutical Research 23, 1675–1686.
51. Chiou W.L., Jeong H.Y., Chung S.M. & Wu T.C. (2000). Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharmaceutical Research 17, 135–140.
52. Bailey J., Knight A. & Balcombe J. (2005). The future of teratology research is in vitro. Biogenic Amines 19, 97–145.
53. Bailey J. (2008). Developmental toxicity testing: Protecting future generations? ATLA 36, 718–721.
54. Basketter D.A., Clewell H., Kimber I., Rossi A., Blaauboer B., Burrier R., Daneshian M., Eskes C., Goldberg A., Hasiwa N., Hoffmann S., Jaworska J., Knudsen T.B., Landsiedel R., Leist M., Locke P., Maxwell G., McKim J., McVey E.A., Ouédraogo G., Patlewicz G., Pelkonen O., Roggen E., Rovida C., Ruhdel I., Schwarz M., Schepky A., Schoeters G., Skinner N., Trentz K., Turner M., Vanparys P., Yager J., Zurlo J. & Hartung T. (2012). A roadmap for the development of alternative (non-animal) methods for carcinogenicity testing. ALTEX 29, 41–55.
55. van Meer P.J., Kooijman M., Brinks V., Gispen-de Wied C.C., Silva-Lima B., Moors E.H. & Schellekens H. (2013). Immunogenicity of mAbs in non-human primates during nonclinical safety assessment. MAbs 5, 810–816.
56. Bailey J., Thew M. & Balls M. (2013). An analysis of the use of dogs in predicting human toxicology and drug safety. ATLA 41, 335–350.
57. Bailey J., Thew M. & Balls M. (2014). An analysis of the use of animal models in predicting human toxicology and drug safety. ATLA 42, 181–199.
58. Wang S.J., Hung H.M. & O'Neill R. (2011). Adaptive design clinical trials and trial logistics models in CNS drug development. European Neuropsychopharmacology 21, 159–166.
59. Jang K.J., Mehr A.P., Hamilton G.A., McPartlin L.A., Chung S., Suh K.Y. & Ingber D.E. (2013). Human kidney proximal tubule-on-a-chip for drug transport and nephrotoxicity assessment. Integrative Biology (Cambridge) 5, 1119–1129.
60. Giri S., Braumann U.D., Giri P., Acikgöz A., Scheibe P., Nieber K. & Bader A. (2013). Nano-structured self-assembling peptides as a defined extracellular matrix for long-term functional maintenance of primary hepatocytes in a bioartificial liver modular device. International Journal of Nano-medicine 8, 1525–1539.
61. Ekwall B. (1999). Overview of the final MEIC results: II. The in vitro–in vivo evaluation, including the selection of a practical battery of cell tests for prediction of acute lethal blood concentrations in humans. Toxicology in Vitro 13, 665–673.
62. Mueller D., Krämer L., Hoffmann E., Klein S. & Noor F. (2014). 3D organotypic HepaRG cultures as in vitro model for acute and repeated dose toxicity studies. Toxicology in Vitro 28, 104–112.
63. Krug A.K., Kolde R., Gaspar J.A., Rempel E., Balmer N.V., Meganathan K., Vojnits K., Baquié M., Waldmann T., Ensenat-Waser R., Jagtap S., Evans R.M., Julien S., Peterson H., Zagoura D., Kadereit S., Gerhard D., Sotiriadou I., Heke M., Natarajan K., Henry M., Winkler J., Marchan R., Stoppini L., Bosgra S., Westerhout J., Verwei M., Vilo J., Kortenkamp A., Hescheler J., Hothorn L., Bremer S., van Thriel C., Krause K.H., Hengstler J.G., Rahnenführer J., Leist M. & Sachinidis A. (2013). Human embryonic stem cell-derived test systems for developmental neurotoxicity: A transcriptomics approach. Archives of Toxicology 87, 123–143.
64. Hengstler J.A., Leist M. & Hescheler J. (2013). Briefing paper: The Novel FP7 ESNATS Test Systems of Developmental Toxicity: State-of-the art and Future Perspectives, 8 pp. Paris, France: ARTTIC Project Office. Available at: http://www.esnats.eu/uploads/images/ESNATS_Briefing_paper_13-09-2013.pdf (Accessed 31.08.14).
65. Huh D., Leslie D.C., Matthews B.D., Fraser J.P., Jurek S., Hamilton G.A., Thorneloe K.S., McAlexander M.A. & Ingber D.E. (2012). A human disease model of drug toxicity-induced pulmonary edema in a lung-on-a-chip microdevice. Science Translational Medicine 4, 159ra147.
66. Kim H.J. & Ingber D.E. (2013). Gut-on-a-chip microenvironment induces human intestinal cells to undergo villus differentiation. Integrative Biology (Cambridge) 5, 1130–1140.
67. Moraes C., Mehta G., Lesher-Perez S.C. & Takayama S. (2011). Organs-on-a-chip: A focus on compartmentalized microdevices. Annals of Biomedical Engineering 40, 1211–1227.
68. Yum K., Hong S.G., Healy K.E. & Lee L.P. (2014). Physiologically relevant organs on chips. Biotechnology Journal 9, 16–27.
69. Huh D., Hamilton G.A. & Ingber D.E. (2011). From 3D cell culture to organs-on-chips. Trends in Cell Biology 21, 745–754.
70. Marx U., Walles H., Hoffmann S., Lindner G., Horland R., Sonntag F., Klotzbach U., Sakharov D., Tonevitsky A. & Lauster R. (2012). ‘Human-on-a-chip’ developments: A translational cutting-edge alternative to systemic safety assessment and efficiency evaluation of substances in laboratory animals and man? ATLA 40, 235–257.
71. Mandenius C.F., Andersson T.B., Alves P.M., Batzl-Hartmann C., Björquist P., Carrondo M.J., Chesne C., Coecke S., Edsbagge J., Fredriksson J.M., Gerlach J.C., Heinzle E., Ingelman-Sundberg M., Johansson I., Küppers-Munther B., Müller-Vieira U., Noor F. & Zeilinger K. (2011). Toward preclinical predictive drug testing for metabolism and hepatotoxicity by using in vitro models derived from human embryonic stem cells and human cell lines — A report on the Vitrocellomics EU-project. ATLA 39, 147–171.
72. Cao L., Tan L., Jiang T., Zhu X.C. & Yu J.T. (2014). Induced pluripotent stem cells for disease modeling and drug discovery in neurodegenerative diseases. Molecular Neurobiology, E-pub ahead of print [doi: 10.1007/s12035-014-8867-6].